Loading...
INBS logo

Intelligent Bio Solutions Inc.NasdaqCM:INBS Stock Report

Market Cap US$5.3m
Share Price
n/a
1Y-87.8%
7D-3.6%
1D-2.3%
Portfolio Value
​
View

Intelligent Bio Solutions Inc.

NasdaqCM:INBS Stock Report

Market Cap: US$5.3m

Intelligent Bio Solutions (INBS) Stock Overview

A medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. More details

INBS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Revenue is forecast to grow 35.94% per year

Trading at good value compared to peers and industry

Risk Analysis

Has less than 1 year of cash runway

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap ($5M)

Does not have meaningful revenue ($4M)

+ 2 more risks

INBS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Top Community Narratives

View all narratives

Intelligent Bio Solutions Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Intelligent Bio Solutions
Historical stock prices
Current Share PriceUS$2.16
52 Week HighUS$24.90
52 Week LowUS$2.08
Beta4.17
1 Month Change-8.09%
3 Month Change-12.20%
1 Year Change-87.80%
3 Year Change-99.40%
5 Year Change-99.90%
Change since IPO-99.90%

Recent News & Updates

Recent updates

Analysis Article • Jun 18

The Future of Drug Testing? Fingerprint Tech From Intelligent Bio Solutions (NASDAQ:INBS) Shows Serious Promise

Intelligent Bio Solutions has a new way to test for drugs using fingerprints: it’s quick, portable, and doesn’t require urine cups or saliva swabs. With commercial traction in 24 countries and over 450 active accounts, INBS is now targeting the U.S. market, where over 55 million drug tests are performed annually.
Seeking Alpha • Oct 04

GBS acquires Intelligent Fingerprinting in all-stock deal

GBS (NASDAQ:GBS) said Tuesday it acquired Intelligent Fingerprinting (IFP), expanding the GBS platform of rapid, non-invasive diagnostic testing technologies and its geographical reach. GBS also began the process of changing its corporate name. GBS issued ~3M shares and ~2.4M series C convertible preferred shares to IFP shareholders. Up to 1.6M preferred shares have been reserved for issuance to IFP's shareholders and lenders. Each preferred share is convertible into three GBS shares. Former IFP shareholders entered into a 12-month lock-up agreement on sales of GBS shares and preferred stock issued under the deal. Former majority IFP shareholders have the right to name two board members to GBS' board. With the acquisition, GBS gains access to IFP's product portfolio, current customer base, and manufacturing facility in the U.K. - which complements GBS' development of its own facility at the University of Newcastle, Australia. GBS in Jun. announced an exclusive deal to acquire IFP.
Seeking Alpha • Aug 31

GBS GAAP EPS of -$0.57, revenue of $0.44M

GBS press release (NASDAQ:GBS): FY GAAP EPS of -$0.57. Revenue of $0.44M (-77.8% Y/Y). As of June 30, 2022, the Company’s cash, cash equivalents and marketable securities totaled approximately $8.2 million, compared to approximately $12.6 million on June 30, 2021.
Seeking Alpha • Aug 31

GBS Inc.: Can Its Technology Come Through?

GBS is a biotechnology company aiming to utilize saliva as a medium for developing non-invasive diagnostic tests. The companies pipeline products are targeting both the COVID-19 and Diabetes markets. GBS currently trades at around $3, which is an attractive entry point for investors. However - The high technological risk associated with its technology outweighs the low entry point. Technological Risk mainly stems from the fact that scientific literature disagrees over the reliability and accuracy of using saliva as a diagnostic medium.
Seeking Alpha • Aug 09

GBS Inc.: Pioneering Non-Invasive, Real-Time Diagnostic Testing

GBS Inc. is a developer of pioneering diagnostic platform adaptable to large unmet markets with multiple applications and indications. GBS has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company’s lead products are saliva glucose test and saliva SARS-CoV-2 antibody test.
Analysis Article • Jul 29

Is GBS (NASDAQ:GBS) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

INBSUS Medical EquipmentUS Market
7D-3.6%-1.5%0.6%
1Y-87.8%-19.9%19.5%

Return vs Industry: INBS underperformed the US Medical Equipment industry which returned -19.9% over the past year.

Return vs Market: INBS underperformed the US Market which returned 19.5% over the past year.

Price Volatility

Is INBS's price volatile compared to industry and market?
INBS volatility
INBS Average Weekly Movement15.4%
Medical Equipment Industry Average Movement8.6%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: INBS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: INBS's weekly volatility has decreased from 25% to 15% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201654Harry Simeonidisibs.inc

Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022.

Intelligent Bio Solutions Inc. Fundamentals Summary

How do Intelligent Bio Solutions's earnings and revenue compare to its market cap?
INBS fundamental statistics
Market capUS$5.29m
Earnings (TTM)-US$11.61m
Revenue (TTM)US$3.91m
1.3x
P/S Ratio
-0.4x
P/E Ratio

Is INBS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INBS income statement (TTM)
RevenueUS$3.91m
Cost of RevenueUS$2.06m
Gross ProfitUS$1.85m
Other ExpensesUS$13.46m
Earnings-US$11.61m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-4.86
Gross Margin47.25%
Net Profit Margin-296.77%
Debt/Equity Ratio0%

How did INBS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/10 21:56
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Intelligent Bio Solutions Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey CohenLadenburg Thalmann & Company